Colorectal Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor
Conditions
Brief summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
Detailed description
The first-in-human (FIH) study of BPI-442096 will be an open-label, non-randomized, Phase 1 study utilizing a modified 3+3 dose escalation followed by an expansion phase in patients with KRAS G12 mutation, class-3 BRAF mutation, NF1 LOF mutation or RTK mutation, amplification or rearrangement advanced solid tumors. The primary objective is to determine safety and tolerability of BPI-442096, the MTD and RP2D. The secondary objectives are to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profile, preliminary anti-tumor activity of BPI-442096.
Interventions
DRUGBPI-442096
Subjects will receive BPI-442096 until disease progression
Sponsors
Betta Pharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent; * Age ≥18 and ≤75 years, male and female patients; * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; * Dose escalation phase: histologically or cytologically confirmed locally advanced or metastatic solid tumor patients (excluding HCC patients), who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Dose expansion phase: histologically or cytologically confirmed locally advanced non-small cell lung cancer, pancreatic cancer, colorectal cancer or other diagnosed solid tumor patients (excluding HCC patients), who had disease progression after standard therapy, intolerable to standard therapy, refuse to standard therapy or for whom no standard therapy exists; * Evaluable lesion required for dose escalation phase and at least 1 measurable lesion as per RECIST v1.1 required for dose expansion phase; * Dose expansion only: Patients must have confirmation of tumour mutation status (including KRAS G12, Class-3 BRAF, NF1 LOF mutations, RTK mutations, amplifications or rearrangements). * Adequate organ function;
Exclusion criteria
* Patients who have previously received a SHP2 inhibitor; * Inadequate wash-out of prior therapies described per protocol, which may include anti-tumor therapies, tumor adjuvant drugs, organ or stem cell transplantation, moderate or strong CYP3A inhibitor or inducer; * Patients with severe or unstable systemic disease, unstable/symptomatic CNS metastasis, other malignant tumors, autoimmune disease, ILD, cardiac disease, bleeding or embolic disease, infectious disease, conditions affecting drug swallow and absorption, medical history leading to chronic diarrhea, etc; * Pregnancy or lactation; * Other conditions considered not appropriate to participate in this trial by the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The adverse events (AEs) | Through the Phase I, approximately 24 months | Safety and tolerability will be assessed by monitoring frequency, duration and severity of adverse events (AEs). |
| Determine the recommended Phase II dose (RP2D) | Through the Phase I, approximately 24 months | Number of subjects with dose limiting toxicity |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| t1/2 | Through the Phase I, approximately 24 months | Half-life time |
| AUC0-t | Through the Phase I, approximately 24 months | Area under the concentration-time curve from time 0 to t |
| the objective response rate (ORR） | Through the Phase I, approximately 24 months | The proportion of patients with complete response (CR) and partial response (PR) in all patients |
| Cmax | Through the Phase I, approximately 24 months | Maximum observed concentration |
| Duration of response (DOR） | Through the Phase I, approximately 24 months | The time from the first CR or PR to the first PD or death due to any cause |
| Progression free survival (PFS) | Through the Phase I, approximately 24 months | The time from the date of randomization to disease progression (PD) or death, whichever occurs first |
| Disease control rate (DCR） | Through the Phase I, approximately 24 months | The proportion of patients with CR, PR and stable disease (SD) in all patients |
| Tmax | Through the Phase I, approximately 24 months | Time to reach maximum observed plasma concentration |
Countries
China
Contacts
Primary ContactYilong Wu, Ph.D
Outcome results
None listed